ALK upgrades its full-year outlook

GlobeNewswire

2025/11/13

Inside information

ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe.

Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products.
The EBIT margin is now projected to improve to approximately 26% (previously: 25%), fuelled by revenue growth, gross margin improvements, and optimisations.

The Q3 report, originally due for 13 November 2025, will be published later today, 12 November 2025. The previously announced presentation for investors and analysts will still take place on 13 November 2025 at 13:30 CET.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434

This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

Company release_16_25UK_121125_outlook upgrade

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583062733"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583062733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583062733?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583062733","market":"hk","top_or_hot":-1,"title":"ALK upgrades its full-year outlook","media":"GlobeNewswire","content":"<html><body><p><i>Inside information </i></p> <p>ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe.</p> <ul><li>Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products.<br/><br/></li><li>The EBIT margin is now projected to improve to approximately 26% (previously: 25%), fuelled by revenue growth, gross margin improvements, and optimisations.</li></ul> <p>The Q3 report, originally due for 13 November 2025, will be published later today, 12 November 2025. The previously announced presentation for investors and analysts will still take place on 13 November 2025 at 13:30 CET.</p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information please contact:</b></p> <p><i>Investor Relations</i><b>: </b>Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525<br/><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><i>This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.</i></p> <p><b><i>About ALK</i></b><b><i><br/></i></b><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.</i>  </p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nCompany release_16_25UK_121125_outlook upgrade\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/ZjhiYTZiNmUtZmVhMC00ZTQ2LWI3NGUtMGM1ZTI5YzZhYzYxLTEwMTM4MDQtMjAyNS0xMS0xMi1lbg==/tiny/ALK-Abello.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALK upgrades its full-year outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALK upgrades its full-year outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-11-13 00:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p><i>Inside information </i></p> <p>ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe.</p> <ul><li>Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products.<br/><br/></li><li>The EBIT margin is now projected to improve to approximately 26% (previously: 25%), fuelled by revenue growth, gross margin improvements, and optimisations.</li></ul> <p>The Q3 report, originally due for 13 November 2025, will be published later today, 12 November 2025. The previously announced presentation for investors and analysts will still take place on 13 November 2025 at 13:30 CET.</p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information please contact:</b></p> <p><i>Investor Relations</i><b>: </b>Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525<br/><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><i>This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.</i></p> <p><b><i>About ALK</i></b><b><i><br/></i></b><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.</i>  </p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nCompany release_16_25UK_121125_outlook upgrade\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/ZjhiYTZiNmUtZmVhMC00ZTQ2LWI3NGUtMGM1ZTI5YzZhYzYxLTEwMTM4MDQtMjAyNS0xMS0xMi1lbg==/tiny/ALK-Abello.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALK","symbol_name":"阿拉斯加航空集團有限公司","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186538/0/en/ALK-upgrades-its-full-year-outlook.html","article_id":"2583062733","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583062733","pubTimestamp":1762964160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Inside information  ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ALK":"阿拉斯加航空集团有限公司"},"translate_title":"ALK上调全年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALK":1.5},"content_text":"Inside information  ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded based on the performance in Q3 and the outlook for the remainder of the year. The changes mainly reflect the current business momentum in Europe. Revenue is now expected to grow by 13-15% in local currencies (previously: 12-14%), driven by growth in all sales regions and product lines. Growth will predominantly be attributable to higher volumes, as ALK expects to treat more patients with its allergy immunotherapy (AIT) and anaphylaxis products.The EBIT margin is now projected to improve to approximately 26% (previously: 25%), fuelled by revenue growth, gross margin improvements, and optimisations. The Q3 report, originally due for 13 November 2025, will be published later today, 12 November 2025. The previously announced presentation for investors and analysts will still take place on 13 November 2025 at 13:30 CET. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525Media: Maiken Riise Andersen, tel. +45 5054 1434 This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation. About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.   \nAttachment\n\n\n\nCompany release_16_25UK_121125_outlook upgrade","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}